Practical Dermatology

11/13/2025

🚨 📊 DO ANTIBIOTICS DISRUPT BIOLOGICS IN PsO? A brief report published online in JAMA Dermatology indicates systemic antibiotic use is associated with shorter persistence of biologic therapies in psoriasis. The dose-response effect suggests gut dysbiosis may play a role, according to the authors.

Read more ➡️ https://ow.ly/BwBB50XrbyM



Facebook
Can antibiotics shorten the effectiveness of biologics in psoriasis treatment? A French national study says yes—especially with repeated use. The findings point to gut microbiota disruption as a possible mechanism. Read the latest from JAMA Dermatology.

X / Twitter
🚨 Biologics less durable in psoriasis patients exposed to antibiotics, French study finds. Repeated courses = higher risk of discontinuation. Gut dysbiosis may be the link.

A new study says YES—with repeated antibiotic use linked to earlier biologic dropout. Could gut health be the missing link?
🧬
🧪 Source: JAMA Dermatology, Oct 2023

11/12/2025

🆕📊 REMIX-1/-2 UPDATE: Recently presented pooled data from the REMIX-1/-2 studies shows remibrutinib delivering rapid efficacy for chronic spontaneous urticaria (CSU) patients not responding to H₁-antihistamines. Topline results include favorable safety and a >70% symptom reduction at week 52.

Read more ➡️ https://ow.ly/tKLP50XqCSC

11/11/2025

🔎📊 GOOD NEWS FOR PEMPHIGUS PATIENTS: A new study using data from over 120 million U.S. EHRs finds no increased psychiatric risk in patients with pemphigus, challenging prior assumptions about mental health burden in autoimmune blistering disease. 🧠✨

Read more ➡️ https://ow.ly/fiRf50XqbGT

11/10/2025

🔎📊 STUDY SUPPORTS ENDOTHELIAL BARRIER THEORY: New evidence from a retrospective analysis of over 20 million US patients suggests seborrheic dermatitis is strongly linked to a range of systemic inflammatory diseases like rosacea, IBS, and celiac disease.

Read more ➡️ https://ow.ly/6xNM50XpCJV

11/07/2025

📢👨‍⚕️🚫 FDA ISSUES WARNINGS ON BOTULINUM TOXINS: The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including symptoms consistent with botulism, linked to these unauthorized products.

Read more ➡️ https://ow.ly/2cM550XoBrx

The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded...

11/06/2025

📢 🇬🇧 DELGOCITINIB ACCESS EXPANDED: The National Institute for Health and Care Excellence (NICE) has recommended reimbursement of delgocitinib cream for adult patients with moderate to severe chronic hand eczema (CHE) in England and Wales. Citing data from the DELTA trials, the decision expands the options for patients with limited response to corticosteroids and underscores the need for equitable assessment across diverse skin tones.

Read more ➡️ https://ow.ly/CRiE50Xo5lw

11/05/2025

📰 NEWS: Galderma’s Restylane Lyft just became the first HA filler in the U.S. to be FDA-approved for use in the chin, midface, hands, and facial folds. Backed by 12-month clinical trial data and high patient satisfaction, this expanded indication offers aesthetic practices new options for lower-face contouring.

11/04/2025

🎙️👨‍💼C-SUITE CHAT: THE EVOLVING NEEDS OF THE MODERN PATIENT

In the latest C-Suite Chat, Practical Dermatology sits down with Cutera CEO Taylor Harris to discuss the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs.

📺 Watch here ➡️ https://ow.ly/pXKo50XleVO

Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their...

11/03/2025

📢 🧳 NEW CONFERENCE ALERT: Mark your calendars! The Inaugural H&W Global Dermatology CME Conference will bring leading experts together to confront the burden of eczema and explore emerging treatments on November 12 thru 16, 2025, at The Sanctuary at Kiawah Island, SC. Conference co-chairs Drs. Firas Hougeir and Jonathan Weiss are calling for earlier intervention and greater integration of global best practices. Don't miss it!

🔍 Read more ➡️ https://ow.ly/N4yv50XlOY0

11/03/2025

💡 NOVEMBER IS NATIONAL HEALTHY SKIN MONTH, a timely reminder of the critical role dermatologists play in preventive care, patient education, and clinical innovation. Dermatologists remain the trusted and proven authorities on all things skin when it comes to protection, prevention, and confidence.🌟

📚 Stay up to date on the latest in dermatology news at ➡️ https://ow.ly/42bx50Xlh2K

11/01/2025

📢 🙋PSORIASIS ADVOCACY: International Federation of Psoriasis Associations (IFPA) executive director Frida Dunger discusses her organization's efforts to raise awareness, including a recent event involving the United Nations as well the recent World Psoriasis Day.

Watch here ➡️ https://ow.ly/5MBz50Xl9Oq

International Federation of Psoriasis Associations (IFPA) executive director Frida Dunger discusses her organization's efforts to raise awareness,...

10/31/2025

📚🔎ATOPIC DERMATITIS JOURNAL CLUB: Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, and editorial board member Brad Glick, DO, MPH, FAAD, discuss a recent article in the Archives of Dermatological Research about combination therapy with dupilumab and omalizumab for atopic dermatitis. 🎙️👨‍⚕️👨‍⚕️

📺 Watch here ➡️ https://ow.ly/gUix50Xh2Ex